CDKN2A and meningioma: In our study, MTAP expression showed 100% (41/41) specificity at the 1:100 dilution and 95% (39/41) specificity at the 1:1200 dilution for identifying meningiomas with intact CDKN2A status and 100% (2/2) sensitivity for detecting meningiomas with CDKN2A homozygous loss.